ACADIA Pharmaceuticals
Filed with the SEC on · accession 0001193125-26-447794
ACAD filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. ACADIA Pharmaceuticals filed its quarterly 10-Q report for Q3 2026, disclosing financial results including revenue from Daybue and Nuplazid, R&D and SG&A expenses, and various license agreements. The stock moved -1.1% by the first close after the filing.
ACADIA Pharmaceuticals filed its quarterly 10-Q report for Q3 2026, disclosing financial results including revenue from Daybue and Nuplazid, R&D and SG&A expenses, and various license agreements. No single major corporate event is disclosed in the filing.
Close before
$21.47
Nov 4, 2026
First close after
-1.07%
$21.24
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for ACAD, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for ACAD?
Click hereACAD filed a 10-Q (SEC filing). ACADIA Pharmaceuticals filed its quarterly 10-Q report for Q3 2026, disclosing financial results including revenue from Daybue and Nuplazid, R&D and SG&A expenses, and various license agreements. No single major corporate event is disclosed in the filing.
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
ACAD closed at $21.47 before the filing and $21.24 on Nov 5, 2026 (-1.07%).
Get alerts when ACAD files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days